ABBOTT INDIA LIMITED
- Country
- 🇮🇳India
- Ownership
- Private
- Established
- 1888-01-01
- Employees
- 73K
- Market Cap
- $7.5B
- Website
- http://www.abbott.com
A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Adalimumab 40 mg subcutaneous (SC) every other week (EOW)
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2011-11-22
- Lead Sponsor
- Abbott
- Target Recruit Count
- 796
- Registration Number
- NCT00233571
Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2008-07-22
- Lead Sponsor
- Abbott
- Target Recruit Count
- 2000
- Registration Number
- NCT00233532
Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2007-04-24
- Lead Sponsor
- Abbott
- Target Recruit Count
- 160
- Registration Number
- NCT00233558
- Locations
- 🇺🇸
Global Medical Information - Abbott, North Chicago, Illinois, United States
A 16 Week Comparative Study of Fenofibrate Versus Ezetimibe as Add-on Therapy to Atorvastatin
- Conditions
- Hyperlipidemia
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2007-10-04
- Lead Sponsor
- Abbott
- Target Recruit Count
- 174
- Registration Number
- NCT00195793
Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: AdalimumabDrug: Placebo
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-08-26
- Lead Sponsor
- Abbott
- Target Recruit Count
- 619
- Registration Number
- NCT00195702
- Locations
- 🇺🇸
Site Ref # / Investigator 358, Voorhees, New Jersey, United States
🇺🇸Site Ref # / Investigator 60736, Anaheim, California, United States
🇺🇸Site Ref # / Investigator 712, Danbury, Connecticut, United States
Long Term Safety and Tolerability Study in Approximately 350 Subjects With Moderate to Severe Chronic, Non-malignant Pain
- Conditions
- Moderate to Severe Chronic, Non-malignant Pain
- Interventions
- Drug: Hydrocodone/Acetaminophen on Extended Release
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-01-19
- Lead Sponsor
- Abbott
- Target Recruit Count
- 431
- Registration Number
- NCT00195728
- Locations
- 🇺🇸
Site Ref # / Investigator 1813, Clearwater, Florida, United States
🇺🇸Site Reference # / Investigator 1741, Raleigh, North Carolina, United States
🇺🇸Site Reference # / Investigator 1719, Virginia Beach, Virginia, United States
Long Term Open Label Continuation Study
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Adalimumab
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2012-08-31
- Lead Sponsor
- Abbott
- Target Recruit Count
- 846
- Registration Number
- NCT00195650
- Locations
- 🇺🇸
Site Reference ID/Investigator# 541, Danbury, Connecticut, United States
🇺🇸Site Reference ID/Investigator# 574, Fort Myers, Florida, United States
🇺🇸Site Reference ID/Investigator# 646, Statesville, North Carolina, United States
Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease
- Conditions
- Crohn's Disease
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-07-12
- Lead Sponsor
- Abbott
- Target Recruit Count
- 777
- Registration Number
- NCT00195715
- Locations
- 🇺🇸
Site Ref # / Investigator 1881, Annapolis, Maryland, United States
🇺🇸Site Ref # / Investigator 1878, Arlington Heights, Illinois, United States
🇺🇸Site Ref # / Investigator 1827, Clearwater, Florida, United States
Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis
- Conditions
- Ankylosing Spondylitis
- Interventions
- Biological: adalimumab (D2E7)Biological: placebo
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Abbott
- Target Recruit Count
- 82
- Registration Number
- NCT00195819
- Locations
- 🇨🇦
Site Ref # / Investigator 64, Winnipeg, Manitoba, Canada
🇨🇦Site Ref # / Investigator 74, Calgary, Alberta, Canada
🇨🇦Site Ref # / Investigator 70, Edmonton, Alberta, Canada
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- Abbott
- Target Recruit Count
- 1469
- Registration Number
- NCT00195676
- Locations
- 🇺🇸
Site Reference ID/Investigator# 1268, Tyler, Texas, United States
🇺🇸Site Reference ID/Investigator# 2434, Columbus, Ohio, United States
🇺🇸Site Reference ID/Investigator# 1683, Boston, Massachusetts, United States